share_log

榮昌生物：海外監管公告 - 2024年度向特定對象發行A股股票預案

REMEGEN: Overseas Regulatory Announcement - Proposal on the Offering of A Shares to Specific Target Subscribers in FY2024

香港交易所 ·  Apr 1 18:23
Summary by Moomoo AI
榮昌生物製藥（煙台）股份有限公司（「榮昌生物」）於2024年3月29日宣布，計劃向特定對象發行A股股票，募集資金總額不超過255,000.00萬元，用於新藥研發項目。本次發行股票數量不超過70,763,170股，發行完成後，公司總股本和净资产將相應增加，但募集資金的使用和實施需要一定的時間。公司預計未來幾年將持續存在大規模的研發投入，且存在繼續虧損的風險。為保護投資者利益，公司將採取一系列措施提升公司競爭力，以填補股東回報。公司全體控股股東、實際控制人及全體董事、高級管理人員對公司本次向特定對象發行股票摊薄即期回報采取填補措施事宜作出了承諾。
榮昌生物製藥（煙台）股份有限公司（「榮昌生物」）於2024年3月29日宣布，計劃向特定對象發行A股股票，募集資金總額不超過255,000.00萬元，用於新藥研發項目。本次發行股票數量不超過70,763,170股，發行完成後，公司總股本和净资产將相應增加，但募集資金的使用和實施需要一定的時間。公司預計未來幾年將持續存在大規模的研發投入，且存在繼續虧損的風險。為保護投資者利益，公司將採取一系列措施提升公司競爭力，以填補股東回報。公司全體控股股東、實際控制人及全體董事、高級管理人員對公司本次向特定對象發行股票摊薄即期回報采取填補措施事宜作出了承諾。
Wing Cheong Biopharmaceuticals (Yantai) Co., Ltd. (“Wing Cheong Biologics”) announced on March 29, 2024 that it plans to issue A shares to certain audiences with a total of no more than 255,000.00 million yuan for new drug R&D projects. The number of shares issued in this time does not exceed 70,763,170 shares. After the issuance is completed, the total share capital and net assets of the company will increase accordingly, but the use and implementation of the raising funds will take some time. The company expects continued large-scale R&D investments in the coming years and risks continuing losses. To protect the interests of investors, the company will take a series of measures to improve the company's competitiveness in order to replenish shareholder returns. All of the Company's controlling shareholders, effective controllers and all directors and senior management have undertaken to take remedial measures for the Company's issuance of shares to specific entities this time.
Wing Cheong Biopharmaceuticals (Yantai) Co., Ltd. (“Wing Cheong Biologics”) announced on March 29, 2024 that it plans to issue A shares to certain audiences with a total of no more than 255,000.00 million yuan for new drug R&D projects. The number of shares issued in this time does not exceed 70,763,170 shares. After the issuance is completed, the total share capital and net assets of the company will increase accordingly, but the use and implementation of the raising funds will take some time. The company expects continued large-scale R&D investments in the coming years and risks continuing losses. To protect the interests of investors, the company will take a series of measures to improve the company's competitiveness in order to replenish shareholder returns. All of the Company's controlling shareholders, effective controllers and all directors and senior management have undertaken to take remedial measures for the Company's issuance of shares to specific entities this time.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more